{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:30:38Z","timestamp":1750926638397},"reference-count":14,"publisher":"Baishideng Publishing Group Inc.","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Acquired haemophilia (AH) is a serious autoimmune haematological disease caused by the production of auto-antibodies against coagulation factor VIII. In some patients, AH is associated with a concomitant malignancy. In case of surgical intervention, AH poses a high risk of life-threatening bleeding.<\/jats:p>\n          <jats:p>CASE SUMMARY<\/jats:p>\n          <jats:p>A 60-year-old female patient with multiple recurrences of non-muscle invasive bladder cancer underwent transurethral tumour resection. A severe haematuria developed postoperatively warranting two endoscopic revisions; however, no clear source of bleeding was identified in the bladder. Subsequent haematological examination established a diagnosis of AH. Treatment with factor VIII inhibitor bypass activity and immunosuppressive therapy was initiated immediately. The patient responded well to the therapy and was discharged from the hospital 21 d after the primary surgery. At the 38-mo follow-up, both AH and bladder cancer remained in complete remission.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>AH is a rare, life-threatening haematological disease. AH should be considered in patients with persistent severe haematuria or other bleeding symptoms, especially if combined with isolated activated partial thromboplastin time prolongation.<\/jats:p>","DOI":"10.12998\/wjcc.v11.i22.5338","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T01:08:49Z","timestamp":1691024929000},"page":"5338-5343","source":"Crossref","is-referenced-by-count":3,"title":["Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report"],"prefix":"10.12998","volume":"11","author":[{"given":"Kate\u0159ina","family":"Ry\u0161\u00e1nkov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarom\u00edr","family":"Gumulec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Grepl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Krhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2023,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2020.1836726"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01066.x"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.230771"},{"key":"B5","unstructured":"EAU Guidelines.   Non-muscle-invasive Bladder Cancer (TaT1 and CIS). [cited 10 January 2023]. Available from: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02433.x"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S77332"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.07.007"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1027-y"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13355"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-03-0183"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.12.005"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.03.024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04654.x"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i22\/5338.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i22\/5338.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T11:57:11Z","timestamp":1699963031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i22\/5338.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,6]]},"references-count":14,"journal-issue":{"issue":"22"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v11.i22.5338","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,6]]}}}